Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tauns Laboratories's Enterprise Value is 円67,339 Mil.
Tauns Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円173 Mil. Therefore, Tauns Laboratories's EV-to-EBIT ratio for today is 388.96.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Tauns Laboratories's Enterprise Value is 円67,339 Mil.
Tauns Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円889 Mil. Therefore, Tauns Laboratories's EV-to-EBITDA ratio for today is 75.78.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Tauns Laboratories's Enterprise Value is 円67,339 Mil.
Tauns Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円5,775 Mil. Therefore, Tauns Laboratories's EV-to-Revenue ratio for today is 11.66.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Tauns Laboratories (TSE:197A) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Tauns Laboratories's current Enterprise Value is 円67,339 Mil.
Tauns Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円173 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Tauns Laboratories's current Enterprise Value is 円67,339 Mil.
Tauns Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円889 Mil.
Tauns Laboratories's current Enterprise Value is 円67,339 Mil.
Tauns Laboratories's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,775 Mil.
Tauns Laboratories's current Enterprise Value is 円67,339 Mil.
Tauns Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
Tauns Laboratories's current Enterprise Value is 円67,339 Mil.
Tauns Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories Enterprise Value Related Terms
Tauns Laboratories Enterprise Value Historical Data
* Premium members only.
The historical data trend for Tauns Laboratories's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Tauns Laboratories's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories (TSE:197A) has a Enterprise Value of 円67,339 Mil as of Jul. 18, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tauns Laboratories and its competitors.
Is Tauns Laboratories' Enterprise Value too high?
Tauns Laboratories' current Enterprise Value is 円67,339 Mil. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Enterprise Value compare to ISRG and BDX?
Tauns Laboratories' Enterprise Value of 円67,339 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tauns Laboratories and its competitors. Tauns Laboratories's current Enterprise Value is 円67,339 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Enterprise Value of 円67,339 Mil. The current Enterprise Value is 円67,339 Mil. Tauns Laboratories' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Enterprise Value is 円67,339 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score
Get the complete analysis for TSE:197A
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
